Sendur M A N, Aksoy S, Zengin N, Altundag K
Ankara Numune Education and Research Hospital, Department of Medical Oncology, Ankara, Turkey.
J BUON. 2013 Oct-Dec;18(4):838-44.
To compare the efficacy of adjuvant anastrozole and letrozole in hormone receptor-positive postmenopausal patients with early breast cancer.
A total of 569 hormone receptor-positive postmenopausal early breast cancer patients were included and analyzed in this study. Of them 238 were taking adjuvant anastrozole and 331 adjuvant letrozole. Demographic and medical data including age, menopausal status, weight, height, treatment history and comorbid diseases were collected from their medical charts.
In both anastrozole and letrozole users, the baseline clinicopathologic characteristics and the treatment history with radiotherapy and chemotherapy were similar. The median patient follow-up was 26.4 months. In the anastrozole arm disease free survival (DFS) was 94.9, 81.3 and 66.0%, whereas in the letrozole arm DFS was 90.6, 78.7 and 68.5% in the first, third and fifth years, respectively (p=0.25). Median overall survival (OS) could not be reached due to the low number of events in both arms. Three-year survival rate in the anastrozole arm was 98.8%, whereas in the letrozole arm it was 96.7% (p = 0.20).
This study showed that both letrozole and anastrozole have similar effects on DFS and OS in the adjuvant hormonal treatment of postmenopausal hormone receptor-positive breast cancer. We believe that this retrospective study is the first to directly compare the efficacy of letrozole and anastrozole.
比较阿那曲唑和来曲唑对激素受体阳性绝经后早期乳腺癌患者的辅助治疗效果。
本研究纳入并分析了569例激素受体阳性绝经后早期乳腺癌患者。其中238例服用阿那曲唑进行辅助治疗，331例服用来曲唑进行辅助治疗。从他们的病历中收集人口统计学和医学数据，包括年龄、绝经状态、体重、身高、治疗史和合并疾病。
服用阿那曲唑和来曲唑的患者，其基线临床病理特征以及放疗和化疗治疗史相似。患者的中位随访时间为26.4个月。在阿那曲唑组，1年、3年和5年无病生存率（DFS）分别为94.9%、81.3%和66.0%；而在来曲唑组，1年、3年和5年DFS分别为90.6%、78.7%和68.5%（p = 0.25）。由于两组事件数较少，均未达到中位总生存期（OS）。阿那曲唑组的3年生存率为98.8%，而来曲唑组为96.7%（p = 0.20）。
本研究表明，在绝经后激素受体阳性乳腺癌的辅助激素治疗中，来曲唑和阿那曲唑对DFS和OS的影响相似。我们认为，这项回顾性研究首次直接比较了来曲唑和阿那曲唑的疗效。
